Evidence map›Paper›PMID 41688712›Full record

ArticleCommunications medicine2026

Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.

Afrah Khairallah, Zesuliwe Jule, Alice Piller, Mallory Bernstein, Kajal Reedoy, Yashica Ganga, Sashkia R Balla, Prudence Kgagudi, Bernadett I Gosnell, Farina Karim and 6 more

Abstract read
In one paragraph

Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Afrah KhairallahAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0003-4838-7032
Zesuliwe JuleAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.
Alice PillerAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0002-0158-3637
Mallory BernsteinAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0001-7498-2391
Kajal ReedoyAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.
Yashica GangaAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.
Sashkia R BallaNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Prudence KgagudiNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Bernadett I GosnellDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0002-6336-7489
Farina KarimAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.
Mahomed-Yunus S MoosaDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0001-6191-4023
Thumbi Ndung'uAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0003-2962-3992
Thandeka Moyo-GweteNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-8719-4028
Khadija KhanAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0001-7565-7400
Alex SigalAfrica Health Research Institute and University of KwaZulu-Natal, Durban, South Africa. alex.sigal@ahri.org.ORCID http://orcid.org/0000-0001-8571-2004

Funding

Gates Foundation INV-018944
6 · The paper itself

Abstract

backgroundSevere Covid-19 leads to higher neutralizing antibody levels, a key correlate of protection. However, the host proteins associated with this response have not been fully characterized. We asked which proteins in the blood plasma associate with neutralization, anti-spike antibody levels, and disease severity in a South African cohort upon first SARS-CoV-2 exposure.

methodsWe used a longitudinal observational cohort design to collect blood at 6 days (acute infection) and 32 days (convalescence) post-diagnosis. We performed SomaScan proteomics on acute blood plasma and measured SARS-CoV-2 plasma neutralization capacity and anti-spike antibody levels in convalescent plasma. Disease severity was scored based on requirement for supplemental oxygen and was mild to moderate (no critically ill participants).

resultsWe find differentially expressed proteins associating with neutralization, anti-spike antibody levels, and disease severity, with strong overlap between proteins associated with neutralization and spike binding, and moderate overlap between neutralization and disease severity. High neutralizers, regardless of requirement for supplemental oxygen, are found to have risk factors and markers for being more ill compared to low neutralizers. We can reasonably predict who becomes a high neutralizer based on individual proteins. The best predictor for neutralization is HSPA8, known to bind viral proteins and cross-present extracellular antigens. The strongest associated pathway is fatty acid metabolism, whose inhibition results in suppression of viral replication.

conclusionsThese results show that host proteins and pathways involved early in SARS-CoV-2 infection associate with neutralizing antibody levels elicited by the infection at convalescence.

Identifiers

PMID41688712
PMCPMC13066479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.